NASDAQ:ARTV Artiva Biotherapeutics Q4 2025 Earnings Results & Report $6.94 +0.14 (+2.06%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$6.92 -0.03 (-0.36%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Artiva Biotherapeutics beat analyst earnings expectations in its Q4 2025 results, released March 10, 2026. The company reported EPS of -$0.84 versus the -$0.87 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 10, 2026TimeAfter Market ClosesConference Call7:00 AM ET Artiva Biotherapeutics EPS ResultsActual EPS-$0.84Consensus EPS -$0.87Beat/MissBeat by +$0.03One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersArtiva Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsArtiva Biotherapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Artiva Biotherapeutics Q4 2025 Earnings FAQ Did Artiva Biotherapeutics beat earnings estimates for Q4 2025? Artiva Biotherapeutics (NASDAQ:ARTV) reported earnings of -$0.84 per share for Q4 2025, beating the consensus estimate of -$0.87. The report was announced on Tuesday, March 10, 2026. When is Artiva Biotherapeutics' next earnings date? Artiva Biotherapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Artiva Biotherapeutics on the company's earnings history page. Artiva Biotherapeutics Earnings HeadlinesArtiva Biotherapeutics (NASDAQ:ARTV) Stock: Insider Fred Aslan Sells 23,463 SharesOctober 9 at 5:24 AM | americanbankingnews.comArtiva Biotherapeutics (NASDAQ:ARTV) Stock: Insider Christopher Horan Sells 10,340 SharesOctober 8 at 5:22 AM | americanbankingnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. | The Oxford Club (Ad)Artiva Biotherapeutics (NASDAQ:ARTV) Stock: Insider Jennifer Bush Sells 8,370 SharesOctober 8 at 5:22 AM | americanbankingnews.comArtiva Biotherapeutics (NASDAQ:ARTV) Stock: Insider Fred Aslan Sells 61,696 SharesOctober 8 at 4:39 AM | americanbankingnews.comCritical Analysis: REGENXBIO (NASDAQ:RGNX) vs. Artiva Biotherapeutics (NASDAQ:ARTV)October 4, 2026 | americanbankingnews.comSee More Artiva Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Artiva Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artiva Biotherapeutics and other key companies, straight to your email. Email Address About Artiva BiotherapeuticsArtiva Biotherapeutics (NASDAQ:ARTV) (NASDAQ:ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient. Artiva’s lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis. The company is also studying its NK cell platform in hematologic malignancies and other diseases in which targeted depletion of abnormal or harmful B cells may have therapeutic value. Artiva is based in San Diego, California, and is focused on advancing its cell therapy candidates through clinical development and toward potential commercialization. Its programs remain investigational and have not been approved by regulatory authorities for general use.View Artiva Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
